Elevated plasma Pim‐1 and its clinical significance in patients with pulmonary arterial hypertension

摘要

Abstract This study was aimed to determine plasma Pim‐1 levels in patients with pulmonary arterial hypertension ( PAH ) and to estimate the clinical value of Pim‐1 as a biomarker of PAH . This was a single‐centre retrospective study in 111 patients with congenital heart disease ( CHD ) and idiopathic PAH ( IPAH ). Those CHD patients were divided into two groups: PAH associated with CHD ( PAH ‐ CHD ) and CHD without PAH ( nPAH ‐ CHD ). Plasma Pim‐1 levels were measured by enzyme‐linked immunosorbent assay. (a) Plasma Pim‐1 levels were significantly increased in patients with PAH ‐ CHD and IPAH compared with the healthy control group (27.81?±?11.34?ng/mL vs 13.02?±?5.30?ng/mL; 32.81?±?12.28?ng/mL vs 13.02?±?5.30?ng/mL, P? ? 0.05) and nPAH ‐ CHD (27.81?±?11.34?ng/mL vs 17.33?±?7.99?ng/mL; 32.81?±?12.28?ng/mL vs 17.33?±?7.99?ng/mL, P ??0.05). Pim‐1 levels were substantially increased in patients with severe PAH ‐ CHD compared with mild‐to‐moderate PAH ‐ CHD (19.12?±?6.70?ng/mL vs 8.54?±?3.71?ng/mL, P ??0.05). (b) Pim‐1 levels were correlated positively with the mean pulmonary artery pressure ( mPAP ) and pulmonary vascular resistance ( PVR ) ( r ?=?0.582, 0.516; P ??0.001, respectively), while negatively with tricuspid annular plane systolic excursion ( TAPSE ), tricuspid annular plane systolic velocity (S’) and right ventricular fractional area changes ( RVFAC ) ( r ?=??0.375, ?0.354, ?0.507; P ??0.05, respectively). (c) PAH ‐ CHD and severe PAH ‐ CHD was identified by plasma Pim‐1 with a cutoff value of 16.8?ng/mL ( P ??0.001) with a sensitivity of 87.3% and a specificity of 65%, and a cutoff value of 20.53?ng/mL ( P ??0.001) with a sensitivity of 87.3% and a specificity of 52%, respectively. Plasma Pim‐1 levels were significantly higher in patients with PAH ‐ CHD and IPAH . Plasma Pim‐1 may represent an effectively biomarker in patients with PAH.